Industries > Pharma > Global Ophthalmic Drugs Market Forecast 2018-2028

Global Ophthalmic Drugs Market Forecast 2018-2028

Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs

PUBLISHED: 26 June 2018
PAGES: 298
PRODUCT CODE: PHA0320
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0320 Categories: , Tags: , , ,

The global ophthalmic drugs market is expected to grow at a CAGR of 4.4% in the first half of the forecast period. The market is expected to grow at a CAGR of 4.8% from 2017-2028. The market is estimated at $24bn in 2017, dominated by the retinal disorder drugs segment.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 298-page report you will receive 123 tables and 113 figures– all unavailable elsewhere.

The 298-page report provides clear detailed insight into the global ophthalmic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Ophthalmic Drugs market forecasts from 2017-2028

• This report also breaks down the revenue forecasts to 2028 for the global ophthalmic drugs market by the leading submarkets:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs

• This report includes revenue forecasts to 2028 for the following ophthalmic drugs:
• Eylea
• Lucentis
• Avastin
• Visudyne
• Jetrea
• Pataday
• Vigamox
• Patanol
• TobraDex
• Cravit
• AzaSite
• Acular
• Lumigan and Ganfort
• Xalatan/Xalacom
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Azopt
• Trusopt
• Zioptan
• Cosopt
• Tapros/Taflotan
• Restasis
• Refresh
• Hyalein
• Diquas

Global Ophthalmic Drugs Market Forecast 2018-2028

• This report provides individual revenue forecasts to 2028 for these national markets:
• The US
• Japan
• EU5: Germany, France, the UK, Spain, Italy
• Russia
• China
• India
• Brazil
• Rest of the World

• Our study provides a SWOT analysis and discusses Porter’s Five Forces analysis that influence the global ophthalmic drugs market

• Our report provides discussion on the ophthalmic drugs that are currently in the development pipeline

• Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
• Novartis
• Regeneron
• Allergan
• Roche
• Valeant
• Santen
• Bayer
• Pfizer
• Senju

Visiongain’s study is intended for anyone requiring commercial analyses for the global ophthalmic drugs market. You find data, trends and predictions.

Buy our report today Global Ophthalmic Drugs Market Forecast 2018-2028: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Ophthalmic Drugs Market Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Ophthalmic Drugs Market Forecast 2018-2028


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category